investig
aberr
express
plasma
protein
patient
pancreat
cancer
highabund
plasma
protein
albumin
transferrin
haptoglobin
igg
iga
deplet
use
immunoaffin
column
lowabund
one
separ
five
fraction
anionexchang
chromatographi
fraction
plasma
protein
subject
highli
sensit
fluoresc
dye
quantit
protein
express
profil
obtain
compar
two
plasma
protein
mixtur
one
five
noncanc
bear
healthi
donor
five
patient
pancreat
cancer
among
protein
spot
found
protein
spot
differ
express
two
mixtur
upregul
six
downregul
cancer
mass
spectrometri
databas
search
allow
identif
protein
correspond
gel
spot
upregul
leucinerich
lrg
previous
implic
pancreat
cancer
observ
western
blot
antilrg
antibodi
valid
upregul
lrg
independ
seri
plasma
sampl
healthi
control
patient
chronic
pancreat
patient
pancreat
cancer
result
demonstr
applic
combin
multidimension
liquid
chromatographi
plasma
proteom
suggest
clinic
util
lrg
plasma
level
measur
pancreat
cancer
fifth
lead
caus
cancer
death
japan
fourth
unit
state
lack
specif
symptom
earli
stage
limit
diagnost
method
lack
respons
present
treatment
mortal
rate
pancreat
adenocarcinoma
highest
among
cancer
type
inde
year
pancreat
adenocarcinoma
caus
death
japan
unit
state
major
patient
pancreat
cancer
local
advanc
diseas
distant
metastas
time
diagnosi
case
surgic
inoper
contrast
surviv
rate
patient
undergo
resect
reach
therefor
earli
diagnosi
potenti
resect
stage
improv
patient
surviv
plasma
prefer
specimen
earli
diagnosi
malign
tumor
sampl
easili
avail
lessinvas
method
although
extens
effort
focus
find
candid
plasma
tumor
marker
mani
candid
list
none
yet
proven
clinic
use
wide
use
marker
pancreat
cancer
often
elev
benign
cholang
pancreat
therefor
lack
specif
need
detect
potenti
curabl
lesion
therefor
discov
practic
plasma
tumor
marker
pancreat
cancer
lead
better
prognosi
novel
technolog
requir
quantifi
lowabund
plasma
protein
larg
sampl
set
recent
newli
emerg
proteom
approach
unravel
plasma
proteom
proteom
method
base
mass
spectrometri
array
technolog
liquid
chromatographi
freeflow
electrophoresi
gel
electrophoresi
combin
appli
plasma
proteom
although
far
comprehens
approach
success
creat
catalog
plasma
protein
identifi
candid
tumor
marker
pancreat
cancer
nevertheless
valid
candid
tumor
marker
yet
complet
real
potenti
benefit
patient
still
unknown
addit
exist
proteom
technolog
fulli
develop
cancer
plasma
proteom
term
tumor
marker
discoveri
like
candid
marker
present
plasma
thu
addit
valid
present
candid
tumor
marker
need
continu
improv
exist
proteom
method
appli
tumor
marker
develop
paper
compar
plasma
sampl
patient
pancreat
cancer
noncanc
bear
healthi
donor
use
combin
multidimension
liquid
chromatographi
twodimension
differ
gel
electrophoresi
protein
label
fluoresc
dye
prior
load
intern
common
standard
sampl
label
differ
fluoresc
dye
geltogel
variat
cancel
quantit
proteom
profil
achiev
across
multipl
sampl
howev
reveal
plasma
proteom
particular
shortcom
includ
limit
amount
protein
load
onto
gel
small
gel
area
avail
separ
protein
spot
low
sensit
fluoresc
dye
problem
address
modifi
combin
exist
proteom
technolog
end
establish
new
method
plasma
proteom
highabund
plasma
protein
deplet
immunoaffin
column
lowabund
protein
fraction
anionexchang
column
prior
previou
report
appli
protocol
success
identif
plasma
protein
aberrantli
express
lung
cancer
patient
present
paper
use
protocol
examin
plasma
proteom
pancreat
cancer
identifi
candid
plasma
tumor
marker
examin
plasma
five
pancreat
cancer
patient
five
noncanc
bear
healthi
donor
obtain
nation
cancer
center
hospit
ncch
tokyo
japan
tabl
plasma
sampl
valid
experi
obtain
two
institut
ncch
valid
set
tokyo
medic
univers
hospit
tmuh
tokyo
japan
valid
set
set
includ
five
cancer
patient
five
healthi
donor
tabl
set
includ
six
cancer
patient
four
chronic
pancreat
patient
five
healthi
control
tabl
inform
consent
obtain
donor
protocol
approv
institut
review
board
nation
cancer
center
blood
sampl
ml
obtain
donor
tube
contain
disodium
edta
venoject
ii
kit
terumo
tokyo
japan
plasma
recov
centrifug
rpm
min
store
c
use
plasma
protein
separ
use
immunoaffin
column
follow
anionexchang
chromatographi
akta
explor
system
ge
healthcar
bioscienc
piscataway
nj
remov
highli
abund
plasma
protein
use
immunoaffin
column
multipl
affin
remov
column
mm
mm
agil
technolog
wilmington
de
contain
antibodi
albumin
transferrin
haptoglobin
iga
igg
plasma
sampl
l
dilut
l
buffer
agil
technolog
filter
spin
filter
agil
technolog
centrifug
g
min
portion
l
dilut
sampl
appli
immunoaffin
column
elut
buffer
flow
rate
mlmin
min
protein
trap
immunoaffin
column
elut
buffer
b
agil
technolog
flow
rate
mlmin
min
process
repeat
time
column
reequilibr
experi
buffer
flow
rate
mlmin
min
flowthrough
fraction
ml
concentr
l
amicon
molecular
weight
cutoff
kda
centrifug
filter
devic
millipor
billerica
follow
separ
immunoaffin
column
concentr
flowthrough
fraction
dilut
ml
mm
trishcl
ph
appli
resourc
q
column
ml
resin
mm
id
mm
ge
healthcar
bioscienc
flow
rate
mlmin
protein
elut
stepwis
gradient
nacl
follow
mm
min
mm
min
mm
min
mm
min
min
elut
buffer
contain
mm
trishcl
ph
anionexchang
column
recycl
use
mm
trishcl
ph
contain
nacl
interv
elut
step
pump
system
wash
ml
next
elut
buffer
volum
fraction
protein
sampl
concentr
l
amicon
molecular
weight
cutoff
kda
centrifug
filter
devic
plasma
protein
fraction
resourc
q
column
precipit
addit
four
volum
aceton
c
min
follow
centrifug
rpm
min
pellet
airdri
min
dissolv
l
lysi
buffer
contain
urea
thiourea
chap
tritonx
mm
trishcl
ph
protein
concentr
measur
bradford
method
protein
assay
kit
biorad
laboratori
inc
hercul
ca
fluoresc
label
perform
follow
sampl
contain
g
protein
reduc
incub
nmol
tri
phosphin
hydrochlorid
tcep
sigma
aldrich
st
loui
mo
c
min
reduc
protein
sampl
fluoresc
label
incub
nmol
satur
dye
ge
healthcar
bioscienc
c
anoth
min
prepar
purpos
g
plasma
protein
reduc
nmol
tcep
label
nmol
satur
dye
label
reaction
termin
addit
equal
volum
lysi
buffer
contain
mm
dtt
pharmalyt
ge
healthcar
bioscienc
brief
first
dimens
separ
carri
immobilin
drystrip
cm
ph
ge
healthcar
bioscienc
load
g
label
protein
gel
fraction
unfraction
plasma
protein
analysi
respect
strip
rehydr
h
label
protein
sampl
dilut
l
lysi
buffer
contain
mm
dtt
pharmalyt
isoelectr
focus
perform
ipgphor
unit
ge
healthcar
bioscienc
total
kvh
c
isoelectr
focus
strip
equilibr
equilibr
buffer
urea
sd
mm
trishcl
ph
wv
glycerol
mm
dtt
min
second
dimens
separ
perform
gradient
polyacrylamid
gel
ettandalt
twelv
system
ge
healthcar
bioscienc
constant
wattag
w
c
h
prepar
purpos
g
label
protein
sampl
separ
gel
electrophoresi
perform
dark
gel
scan
masterimag
ge
healthcar
bioscienc
spot
detect
quantif
imag
match
perform
decyd
softwar
ge
healthcar
bioscienc
ran
triplic
gel
sampl
reduc
geltogel
variat
ingel
digest
perform
protein
spot
excis
autom
spot
collector
spotpick
ge
healthcar
bioscienc
collect
gel
piec
wash
three
time
l
methanol
gentli
sonic
min
gel
briefli
wash
l
water
dehydr
l
acetonitril
acn
min
acn
min
gel
incub
l
mm
ammonium
bicarbon
min
dehydr
l
acn
min
incub
l
mm
ammonium
bicarbon
min
dehydr
l
mixtur
mm
ammonium
bicarbon
min
gel
complet
dehydr
l
acn
min
twice
air
dri
min
protein
gel
plug
digest
overnight
c
sequencinggrad
modifi
trypsin
promega
madison
wi
tryptic
digest
recov
incub
tfa
twice
recov
peptid
concentr
vacuum
evapor
speedvac
thermo
electron
san
jose
ca
subject
liquid
chromatographytandem
mass
spectrometri
lcmsm
mass
spectrometri
studi
carri
describ
previous
brief
lcmsm
system
compris
paradigm
dual
solvent
deliveri
system
michrom
bioscienc
auburn
ca
hplc
ht
pal
auto
sampler
two
injector
valv
ctc
analyt
zwingen
switzerland
finnigan
ltq
linear
itm
thermo
electron
san
jose
ca
equip
nsi
sourc
amr
inc
tokyo
japan
databas
search
swissprot
perform
mascot
softwar
matrix
scienc
london
uk
http
wwwmatrixsciencecom
msm
data
investig
homo
sapien
subset
sequenc
databas
search
allow
variabl
modif
methionin
residu
oxid
peptid
mass
toler
set
da
fragment
mass
toler
da
protein
hit
two
signific
match
peptid
distinct
sequenc
p
search
paramet
equal
mascot
ion
score
statist
consid
provid
protein
identif
certainti
addit
msm
spectra
identifi
peptid
manual
inspect
western
blot
fluorescencelabel
protein
achiev
accord
previou
report
brief
g
fraction
protein
elut
mm
nacl
fluoresc
label
separ
gel
transfer
onto
nitrocellulos
membran
local
leucinerich
lrg
examin
specif
antibodi
lrg
dilut
abnova
co
ltd
taipei
citi
taiwan
secondari
antibodi
mous
igg
ge
healthcar
bioscienc
use
lrg
dilut
immun
complex
detect
enhanc
ecl
kit
ge
healthcar
bioscienc
monitor
fuji
film
tokyo
japan
plasma
sampl
l
separ
sdspage
transfer
onto
nitrocellulos
membran
differenti
express
lrg
plasma
examin
specif
antibodi
dilut
abnova
co
ltd
secondari
antimous
antibodi
ge
healthcar
bioscienc
use
dilut
immun
complex
detect
band
quantifi
densitometr
analysi
use
scion
imag
softwar
scion
corpor
frederick
md
http
wwwscioncorpcom
statist
analysi
perform
use
statview
softwar
sa
institut
inc
cari
nc
reduc
complex
decreas
dynam
rang
plasma
proteom
protein
fraction
liquid
chromatographi
accord
affin
ionic
properti
fig
highabund
plasma
protein
separ
protein
immunoaffin
column
con
fig
multidimension
separ
plasma
protein
liquid
chromatographi
immunoaffin
column
contain
antibodi
albumin
transferrin
haptoglobin
igg
iga
use
deplet
protein
plasma
sampl
bound
fraction
contain
protein
flowthrough
fraction
contain
less
abund
protein
flowthrough
fraction
subject
subsequ
studi
use
b
anionexchang
column
separ
flowthrough
fraction
immunoaffin
column
plasma
sampl
separ
five
fraction
subsequ
studi
use
reproduc
process
valid
previou
report
tain
antibodi
albumin
transferrin
haptoglobin
iga
igg
fig
flowthrough
fraction
column
subject
anionexchang
column
separ
fig
individu
plasma
sampl
independ
subject
immunoaffin
column
anionexchang
column
separ
fraction
sampl
precipit
aceton
equal
amount
individu
fraction
sampl
combin
creat
two
mixtur
fraction
one
mixtur
sampl
five
healthi
donor
mixtur
sampl
five
cancer
patient
tabl
mixtur
label
perform
differenti
express
studi
also
creat
intern
control
sampl
fraction
fraction
plasma
sampl
healthi
donor
combin
ident
fraction
cancer
patient
label
intern
control
sampl
g
mix
sampl
mixtur
fraction
g
subject
unfraction
plasma
proteom
individu
sampl
g
mix
unfraction
plasma
mixtur
g
donor
list
tabl
imag
obtain
multiplex
imag
fraction
scan
gel
laser
scanner
standard
imag
imag
could
cancel
geltogel
variat
obtain
quantit
result
entir
set
imag
fraction
sampl
shown
fig
imag
intern
control
sampl
patient
mixtur
overlaid
multiplex
imag
increas
number
observ
protein
spot
consist
previou
report
number
spot
imag
mixtur
unfraction
plasma
sampl
healthi
donor
cancer
patient
fig
contrast
fraction
result
increas
observ
number
spot
fig
show
advantag
prefraction
plasma
sampl
look
protein
spot
show
aberr
intens
plasma
sampl
cancer
patient
compar
sampl
versu
noncanc
bear
healthi
donor
small
number
target
protein
bound
immunoaffin
column
observ
fraction
anionexchang
column
data
shown
exclud
protein
differenti
analysi
identifi
mechan
leak
immunoaffin
column
decyd
softwar
select
protein
spot
show
differ
intens
two
mixtur
statist
signific
student
ttest
p
fig
differ
observ
compar
profil
whole
plasma
fig
flowthrough
fraction
anionexchang
chromatographi
amount
protein
small
allow
statist
analysi
protein
spot
protein
spot
intens
spot
upregul
spot
downregul
pancreat
cancer
spot
subject
protein
identif
mass
spectrometri
tabl
protein
spot
identifi
multipl
protein
eight
singl
spot
spot
amino
acid
coverag
differ
candid
protein
factor
approxim
howev
mass
spectrometr
studi
spot
result
identif
three
candid
two
almost
equal
number
identifi
peptid
mascot
score
coverag
rate
tent
consid
protein
highest
peptid
number
highest
mascot
score
highest
coverag
rate
probabl
candid
protein
correspond
spot
number
protein
correspond
protein
spot
increas
protein
correspond
spot
probabl
reflect
posttransl
modif
protein
protein
correspond
spot
show
consist
upor
downregul
contrast
spot
contain
complement
show
inconsist
regul
intens
two
spot
increas
one
spot
decreas
pancreat
cancer
sampl
leucinerich
lrg
identifi
correspond
five
protein
spot
intens
spot
show
increas
pancreat
cancer
aberr
regul
lrg
report
previous
pancreat
cancer
confirm
identif
lrg
use
specif
antibodi
first
protein
mm
nacl
fraction
separ
fig
transfer
onto
nitrocellulos
membran
scan
membran
laser
scanner
local
lrg
membran
fig
membran
react
antilrg
antibodi
confirm
mass
spectrometr
protein
identif
fig
tabl
overlay
imag
protein
onto
ecl
signal
protein
identif
specif
antibodi
could
achiev
accur
way
elev
intens
five
lrg
spot
also
confirm
compar
imag
mixtur
noncanc
bear
healthi
donor
fig
cancer
patient
fig
upregul
lrg
valid
individu
sampl
monitor
express
lrg
multipl
sampl
perform
sdspagewestern
blot
result
identif
consist
upregul
lrg
individu
cancer
patient
fig
compar
individu
noncanc
bear
healthi
donor
fig
elev
express
lrg
pancreat
cancer
confirm
valid
set
tabl
fig
well
valid
set
contain
plasma
sampl
noncanc
bear
healthi
donor
chronic
pancreat
patient
pancreat
cancer
patient
obtain
anoth
institut
tabl
found
plasma
sampl
chronic
pancreat
patient
tend
express
lower
level
lrg
compar
sampl
pancreat
cancer
patient
fig
leucinerich
character
unusu
high
content
leucin
weight
primari
structur
lrg
suggest
may
membraneassoci
membranederiv
protein
although
lrg
correl
granulocyt
differenti
involv
tgfbeta
pathway
biolog
function
site
origin
lrg
still
obscur
aberr
regul
lrg
observ
patient
malign
diseas
viru
infect
previous
report
elev
plasma
level
lrg
lung
cancer
use
proteom
protocol
similar
use
present
studi
recent
yu
et
al
perform
plasma
proteom
studi
pancreat
cancer
use
combin
immunoaffin
column
although
appli
less
stringent
criteria
detect
differenti
express
plasma
protein
statist
fold
differ
consid
upregul
lrg
pancreat
cancer
detect
studi
observ
suggest
anionexchang
chromatographi
may
critic
import
improv
perform
lrg
identifi
sever
express
studi
cellular
protein
pancreat
cancer
use
variou
modal
includ
mass
spectrometri
neither
comprehens
proteom
studi
protein
secret
tissuecultur
pancreat
cancer
cell
use
stabl
isotop
label
amino
acid
cell
cultur
silac
method
result
identif
lrg
thu
plasma
lrg
may
origin
pancreat
cancer
cell
earli
studi
plasma
protein
plasma
lrg
found
increas
bacteri
viral
infect
recent
plasma
fig
b
sever
protein
identifi
one
protein
spot
rank
order
number
peptid
c
access
number
protein
deriv
swissprot
averag
ratio
spot
intens
pancreat
cancer
patientsnoncanc
bear
healthi
donor
e
theoret
molecular
weight
isoelectr
point
obtain
swissprot
f
number
peptid
fragment
score
mascot
search
result
g
amino
acid
sequenc
coverag
proteom
use
identifi
increas
express
lrg
patient
sar
caus
infect
human
sarscoronaviru
sarscov
although
extens
proteom
studi
parallel
use
link
esimsm
isotopecod
affin
tag
technolog
icat
coupl
twodimension
lcmsm
list
mani
protein
associ
infect
sarscov
elev
lrg
observ
infect
cell
observ
suggest
increas
concentr
plasma
lrg
may
due
host
respons
certain
type
malign
diseas
viru
infect
examin
plasma
lrg
express
level
cancer
patient
acut
inflammatori
phase
first
select
cancer
patient
normal
creactiv
protein
crp
concentr
tabl
explor
whether
increas
lrg
level
parallel
dynam
common
acut
phase
protein
second
test
plasma
cancer
patient
normal
level
tabl
tumor
marker
commonli
use
diagnosi
pancreat
cancer
examin
possibl
plasma
lrg
level
use
way
complementari
exist
tumor
marker
sdspagewestern
blot
use
antilrg
antibodi
show
consist
upregul
lrg
patient
neg
crp
andor
compar
noncanc
bear
healthi
donor
fig
therefor
increas
amount
lrg
may
independ
regul
acut
phase
protein
tumor
marker
also
examin
plasma
sampl
chronic
pancreat
patient
tabl
found
tend
express
lower
lrg
level
compar
sampl
pancreat
cancer
patient
fig
correl
express
level
lrg
clinic
inform
larg
sampl
set
hope
valid
util
lrg
biomark
monitor
statu
patient
plasma
sampl
pancreat
cancer
patient
express
high
lrg
level
lead
us
suggest
examin
plasma
lrg
level
combin
exist
biomark
would
increas
specif
sensit
diagnosi
kawakami
et
al
report
increas
amount
plasma
lrg
liver
cancer
patient
treat
radiofrequ
ablat
thu
possibl
applic
plasma
lrg
monitor
effect
treatment
may
also
worth
examin
pancreat
cancer
observ
two
problem
immunoaffin
deplet
method
first
similar
previou
report
target
protein
observ
fraction
anionexchang
column
possibl
reason
leak
includ
specif
antibodi
capac
column
presenc
unknown
substanc
hinder
bind
popul
target
protein
difficult
determin
whether
event
due
technic
reason
true
fig
lrg
level
plasma
sampl
valid
set
examin
sdspagewestern
blot
antilrg
antibodi
sampl
noncanc
bear
healthi
donor
sampl
chronic
pancreat
patient
sampl
pancreat
cancer
patient
follow
ecl
reaction
membran
strip
stain
coomassi
brilliant
blue
cbb
ecl
signal
lrg
protein
normal
intens
cbbstain
membran
rel
lrg
signal
calcul
b
n
noncanc
bear
healthi
donor
pt
chronic
pancreat
patient
p
pancreat
cancer
patient
gray
rhombus
indic
individu
data
black
circl
bar
indic
data
averag
standard
error
group
respect
comparison
mean
perform
use
student
ttest
signific
differ
event
biolog
mean
compar
six
target
protein
noncanc
bear
healthi
donor
cancer
patient
use
unfraction
plasma
sampl
method
signific
differ
observ
second
immunoaffin
method
may
concomitantli
remov
lowabund
protein
bound
carrier
protein
albumin
immunoglobulin
could
analyz
lowabund
protein
report
special
attent
protein
may
requir
plasma
proteom
studi
protein
spot
gel
overlap
across
fraction
anionexchang
chromatographi
even
use
stepwis
gradient
method
system
wash
interv
overlap
spot
express
across
fraction
differ
featur
reveal
anionexchang
column
consid
overlap
spot
correspond
differ
isoform
protein
therefor
count
protein
spot
gel
howev
everi
differenti
express
protein
consid
suitabl
tumor
marker
exampl
spot
transthyretin
differenti
express
cancer
patient
healthi
donor
minut
amount
total
abund
transthyretin
difficult
extract
portion
protein
contrari
lrg
also
differenti
express
cancer
patient
healthi
donor
express
one
fraction
therefor
select
candid
tumor
marker
pancreat
cancer
studi
found
multipl
protein
identifi
eight
singl
spot
tabl
observ
consist
previou
report
other
use
highresolut
narrowrang
ipg
gel
largeformat
second
dimens
gel
could
solv
problem
extent
howev
case
multipl
protein
list
candid
result
mass
spectrometr
protein
identif
differenti
express
candid
protein
confirm
blot
initi
experi
reli
result
studi
fig
